182 related articles for article (PubMed ID: 12363127)
1. Obsessive-compulsive disorder with non-24-hour sleep-wake syndrome.
Morinobu S; Yamashita H; Yamawaki S; Tanaka K; Ohkawa M
J Clin Psychiatry; 2002 Sep; 63(9):838-40. PubMed ID: 12363127
[No Abstract] [Full Text] [Related]
2. Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases.
McDougle CJ; Fleischmann RL; Epperson CN; Wasylink S; Leckman JF; Price LH
J Clin Psychiatry; 1995 Nov; 56(11):526-8. PubMed ID: 7592506
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment for obsessive-compulsive disorder with addition of low-dose risperidone to fluvoxamine: implications for plasma levels of catecholamine metabolites and serum brain-derived neurotrophic factor levels.
Yoshimura R; Kaneko S; Shinkai K; Nakamura J
Psychiatry Clin Neurosci; 2006 Jun; 60(3):389-93. PubMed ID: 16732759
[TBL] [Abstract][Full Text] [Related]
4. Response to fluvoxamine augmentation for obsessive and compulsive symptoms in schizophrenia.
Dwivedi S; Pavuluri M; Heidenreich J; Wright T
J Child Adolesc Psychopharmacol; 2002; 12(1):69-70. PubMed ID: 12014598
[No Abstract] [Full Text] [Related]
5. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.
McDougle CJ; Epperson CN; Pelton GH; Wasylink S; Price LH
Arch Gen Psychiatry; 2000 Aug; 57(8):794-801. PubMed ID: 10920469
[TBL] [Abstract][Full Text] [Related]
6. Euprolactinemic gynecomastia and galactorrhea with risperidone-fluvoxamine combination.
Pratheesh PJ; Praharaj SK; Srivastava A
Psychopharmacol Bull; 2011; 44(1):70-3. PubMed ID: 22506441
[TBL] [Abstract][Full Text] [Related]
7. Augmenting SRIs for Obsessive-Compulsive Disorder: Patient Preference for Risperidone Does Not Limit Effectiveness of Exposure and Ritual Prevention.
Wheaton MG; Carpenter JK; Kalanthroff E; Foa EB; Simpson HB
Psychother Psychosom; 2016; 85(5):314-6. PubMed ID: 27513584
[TBL] [Abstract][Full Text] [Related]
8. Tiagabine augmentation to fluvoxamine-risperidone combination in the treatment of obsessive-compulsive disorder.
Oulis P; Masdrakis VG; Karapoulios E; Karakatsanis NA; Kouzoupis AV; Konstantakopoulos G; Soldatos CR
World J Biol Psychiatry; 2009; 10(4 Pt 3):953-5. PubMed ID: 19224410
[TBL] [Abstract][Full Text] [Related]
9. Risperidone augmentation of paroxetine in a case of severe, treatment-refractory obsessive-compulsive disorder without comorbid psychopathology.
Agid O; Lerer B
J Clin Psychiatry; 1999 Jan; 60(1):55-6. PubMed ID: 10074882
[No Abstract] [Full Text] [Related]
10. The use of sumatriptan in the treatment of obsessive-compulsive disorder in an adolescent.
Pathak S; Cottingham EM; McConville BJ
J Child Adolesc Psychopharmacol; 2003; 13 Suppl 1():S93-4. PubMed ID: 12880505
[No Abstract] [Full Text] [Related]
11. The first Japanese pediatric case of obsessive-compulsive disorder who responded to a selective serotonin re-uptake inhibitor.
Furusho J; Kubagawa T; Saitoh N; Matsuzaki K; Yamakawa H; Iikura Y
Pediatr Int; 2000 Aug; 42(4):451-2. PubMed ID: 10986886
[No Abstract] [Full Text] [Related]
12. Deep Brain Stimulation for OCD in a Patient With Comorbidities: Epilepsy, Tics, Autism, and Major Depressive Disorder.
Davis RA; Winston H; Gault JM; Kern DS; Mikulich-Gilbertson SK; Abosch A
J Neuropsychiatry Clin Neurosci; 2021; 33(2):167-171. PubMed ID: 33535803
[No Abstract] [Full Text] [Related]
13. Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder.
Dell'Osso B; Allen A; Hollander E
Expert Opin Pharmacother; 2005 Dec; 6(15):2727-40. PubMed ID: 16316311
[TBL] [Abstract][Full Text] [Related]
14. Response to risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases.
Berigan TR; Harazin JS
J Clin Psychiatry; 1996 Dec; 57(12):594-5. PubMed ID: 9010126
[No Abstract] [Full Text] [Related]
15. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.
Erzegovesi S; Guglielmo E; Siliprandi F; Bellodi L
Eur Neuropsychopharmacol; 2005 Jan; 15(1):69-74. PubMed ID: 15572275
[TBL] [Abstract][Full Text] [Related]
16. Antiobsessional effect of risperidone add-on treatment in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder may be dose-dependent.
Ramasubbu R
Arch Gen Psychiatry; 2002 May; 59(5):472; author reply 472-3. PubMed ID: 11982460
[No Abstract] [Full Text] [Related]
17. Possible dose-response relationship for risperidone in obsessive-compulsive disorder.
Baker RW
J Clin Psychiatry; 1998 Mar; 59(3):134. PubMed ID: 9541161
[No Abstract] [Full Text] [Related]
18. Fluvoxamine in the treatment of corticosteroid-induced obsessive-compulsive disorder.
Oulis P; Masdrakis VG; Florakis A; Papadimitriou GN
Clin Neuropharmacol; 2009; 32(3):176-7. PubMed ID: 19483493
[No Abstract] [Full Text] [Related]
19. [The treatment of OCD].
Sumitani S; Ohmori T
Ryoikibetsu Shokogun Shirizu; 2003; (38):442-5. PubMed ID: 12877022
[No Abstract] [Full Text] [Related]
20. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders.
Stein DJ; Bouwer C; Hawkridge S; Emsley RA
J Clin Psychiatry; 1997 Mar; 58(3):119-22. PubMed ID: 9108814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
